Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KIR3DL2 mutation
i
Other names:
KIR3DL2, Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2, CD158K, Killer Cell Immunoglobulin-Like Receptor Three Domains Long Cytoplasmic Tail, Killer Cell Immunoglobulin-Like Receptor 3DL2, P70 Natural Killer Cell Receptor Clone CL-5, Natural Killer-Associated Transcript 4, CD158 Antigen-Like Family Member K, MHC Class I NK Cell Receptor, P70 NK Receptor CL-5, NKAT-4, NKAT4, Killer Cell Immunoglobulin-Like Receptor 2DL2, Killer-Cell Immunoglobulin-Like Rece
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3812
Related biomarkers:
Expression
Mutation
‹
KIR3DL2 overexpression (1)
KIR3DL2 overexpression (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KIR3DL2 mutation
HER2 Positive Breast Cancer
KIR3DL2 mutation
HER2 Positive Breast Cancer
trastuzumab + LZM-005
Sensitive: C3 – Early Trials
trastuzumab + LZM-005
Sensitive
:
C3
trastuzumab + LZM-005
Sensitive: C3 – Early Trials
trastuzumab + LZM-005
Sensitive
:
C3
KIR3DL2 mutation
HER2 Positive Breast Cancer
KIR3DL2 mutation
HER2 Positive Breast Cancer
LZM-005
Sensitive: C3 – Early Trials
LZM-005
Sensitive
:
C3
LZM-005
Sensitive: C3 – Early Trials
LZM-005
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.